MA27173A1 - Utilisation de 3-phenyl-5-alcoxy-1,3,4-oxdiazol-2-one substituee pour la fabrication de medicaments a effet inhibiteur sur la lipase pancreatique - Google Patents

Utilisation de 3-phenyl-5-alcoxy-1,3,4-oxdiazol-2-one substituee pour la fabrication de medicaments a effet inhibiteur sur la lipase pancreatique

Info

Publication number
MA27173A1
MA27173A1 MA27804A MA27804A MA27173A1 MA 27173 A1 MA27173 A1 MA 27173A1 MA 27804 A MA27804 A MA 27804A MA 27804 A MA27804 A MA 27804A MA 27173 A1 MA27173 A1 MA 27173A1
Authority
MA
Morocco
Prior art keywords
oxdiazol
alcoxy
drugs
phenyl
substituted
Prior art date
Application number
MA27804A
Other languages
English (en)
French (fr)
Inventor
Karl Schoenafinger
Stefan Petry
Guenter Mueller
Armin Bauer
Hubert Otto Heuer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MA27173A1 publication Critical patent/MA27173A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA27804A 2002-02-28 2004-07-27 Utilisation de 3-phenyl-5-alcoxy-1,3,4-oxdiazol-2-one substituee pour la fabrication de medicaments a effet inhibiteur sur la lipase pancreatique MA27173A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208986A DE10208986A1 (de) 2002-02-28 2002-02-28 Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase

Publications (1)

Publication Number Publication Date
MA27173A1 true MA27173A1 (fr) 2005-01-03

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27804A MA27173A1 (fr) 2002-02-28 2004-07-27 Utilisation de 3-phenyl-5-alcoxy-1,3,4-oxdiazol-2-one substituee pour la fabrication de medicaments a effet inhibiteur sur la lipase pancreatique

Country Status (20)

Country Link
EP (1) EP1482929A1 (de)
JP (1) JP2005519079A (de)
KR (1) KR20040101250A (de)
CN (1) CN1638766A (de)
AR (1) AR038702A1 (de)
AU (1) AU2003210292A1 (de)
BR (1) BR0308045A (de)
CA (1) CA2477005A1 (de)
CO (1) CO5611144A2 (de)
DE (1) DE10208986A1 (de)
HR (1) HRP20040783A2 (de)
HU (1) HUP0500093A2 (de)
IL (1) IL163719A0 (de)
MA (1) MA27173A1 (de)
MX (1) MXPA04007480A (de)
NO (1) NO20044091L (de)
PL (1) PL371310A1 (de)
RU (1) RU2004128932A (de)
TW (1) TW200400026A (de)
WO (1) WO2003072098A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862859B1 (de) 2004-06-17 2018-07-25 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
WO2006045799A2 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
RU2459812C2 (ru) * 2007-12-25 2012-08-27 Киссеи Фармасьютикал Ко., Лтд. Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции
WO2010074587A2 (en) 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
CN103086859B (zh) * 2011-11-08 2015-11-11 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
CN111527065B (zh) * 2017-09-01 2024-05-07 科廷大学 油酰基-溶血磷脂酰肌醇(油酰基-lpi)的合成衍生物及其用途
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
ES2218383T3 (es) * 2000-03-07 2004-11-16 Aventis Pharma Deutschland Gmbh 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas sustituids y su uso para la inhibicion de la lipasa sensible a hormonas.

Also Published As

Publication number Publication date
HRP20040783A2 (en) 2005-04-30
MXPA04007480A (es) 2004-11-10
WO2003072098A1 (de) 2003-09-04
HUP0500093A2 (hu) 2005-04-28
CA2477005A1 (en) 2003-09-04
KR20040101250A (ko) 2004-12-02
AU2003210292A1 (en) 2003-09-09
JP2005519079A (ja) 2005-06-30
TW200400026A (en) 2004-01-01
BR0308045A (pt) 2004-12-21
AR038702A1 (es) 2005-01-26
NO20044091L (no) 2004-09-27
EP1482929A1 (de) 2004-12-08
PL371310A1 (en) 2005-06-13
RU2004128932A (ru) 2005-04-10
CN1638766A (zh) 2005-07-13
IL163719A0 (en) 2005-12-18
DE10208986A1 (de) 2003-09-11
CO5611144A2 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
LU93320I2 (fr) Everolimus ou un sel pharmaceutiquement acceptable de celui-ci
ATE380544T1 (de) Umhüllte feste darreichungsform
NO20053264D0 (no) Innretning for produksjon av honningkakehonning.
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
DK1344893T3 (da) Aktuator med konstant kraft
ATE290837T1 (de) Medikamentenversorgung der sub-tenon
NO20010579L (no) Utforminger på overflaten av et legeme
NO20022645L (no) Farmasöytisk superdisintegrerende stoff
MA27173A1 (fr) Utilisation de 3-phenyl-5-alcoxy-1,3,4-oxdiazol-2-one substituee pour la fabrication de medicaments a effet inhibiteur sur la lipase pancreatique
DE60331753D1 (de) Autonomer schmiermittelspender
ITTO20020157A0 (it) Macchina depallettizzatrice.
PT1135140E (pt) Utilizacao de ibandronato para a promocao da integracao ossea de endoproteses
DE60318661D1 (de) Schmieren des Notlaufrings
FI20021674A0 (fi) Päällystyslaite
AU2002366793A1 (en) Improved lilly of the valley aromachemicals
NO20041295L (no) Tieno(1,3)oksazin-4-oner med lipaseinhiberende aktivitet
FR2843785B1 (fr) Disque d'embrayage
FR2847782B1 (fr) Structure d'entourage d'un sommier de literie.
DE29904638U1 (de) Klemmbarer Lampenschirm
PT9741T (pt) Protector para a parte inferior de uma escora
FR2847783B1 (fr) Structure d'entourage d'un sommier de literie.
PT9740T (pt) Protector para a base de uma escora.
FR2843034B1 (fr) Tremplin de saut pour le roller
ITMI20030747A1 (it) Dispositivo per fissare un'asta di afferramento sulla parte di una cassa.
ITBO990233A0 (it) Apparecchiatura per l' applicazione di una banda sul profilo periferic o circolare di un articolo .